Opitz, Klaus (Munster, DE)

08/238550

05/21/1996

05/05/1994

Images are available in PDF form when logged in. To view PDFs, Login  or  Create Account (Free!)

View patents that cite this patent

Click for automatic bibliography generation

LTS Lohmann Therapie-Systeme GmbH + Co. KG (Neuwied, DE)
Hefa-Frenon Arzneimittel GmbH & Co. KG (Werne, DE)

514/215

514/811

A61K9/70; A61K31/55; A61K31/55

514/215, 514/811

4663318	Method of treating Alzheimer's disease	May, 1987	Davis	514/252
4761429	Enkephalinase and endorphinase inhibitors as anti-craving compositions	August, 1988	Blum et al.	514/561
4777173	Method for treatment of alcohol abuse	October, 1988	Shrotryia et al.	514/561
4954504	N.sub.9 -cyclopentyl-substituted adenine derivatives having adenosine-2 receptor stimulating activity	September, 1990	Chen et al.	514/265
5152994	Rapid method for interrupting or attenuating poly-drug dependency syndromes	October, 1992	Lotsof	424/436

Bickel, U., Thomsen, T., Weber, W., Fischer, J. P., Bachus, R., Nitz, M., Kewitz, H.: "Pharmacokinetics of galanthamine in humans and corresponding cholinesterase inhibition." Clin. Pharmacol. Ther., 50: 420-28 (1991).
Cozanitis, D. A., Toivakka, E.: "Treatment of respiratory depression with the anticholinesterase drug galanthamine hydrobromide." Aneasthesia, 29: 581-84 (1974).
Cozanitis, D. A.: "Galanthamine hydrobromide, a longer acting anticholinesterase drug, in the treatment of the central effects of Scopolamine (Hyoscine)." Anaesthesist, 26: 649-50 (1977).
Cozanitis, D. A., van de Pol, F., van Wezel, H., Crul, J. F.: "Antagonistic activity of galanthamine on constant infusion of pancuronium in rats." Experientia, 37: 1326-27 (1981).
Cozanitis, D. A., Friedmann, T., Furst, S.: "Study of the analgesic effects of Galanthamine, a Cholinesterase Inhibitor." Archives Intern. de Pharmacodynamie et de Therapie, 266: 229-38 (1983).
Foitzik, H., Lawin, P.: "Klinische Erfahrungen mit Galanthamin (Nivalin) als Antidot von Pancuronium." Z. prakt. Anasth., 7: 203-7 (1972).
Gopel, W., Bertram, W.: "Erfahrungen mit Nivalin in der neurologischen Therapie." Psychiat. Neurol. med. Psychol., 23: 712-18 (1971).
Mayrhofer, O.: "Erfahrungen mit Galanthamin (Nivalin als Antagonist der Relaxantien vom Curaretyp." Bull. schweiz. Akad. med. Wiss., 23: 48-52 (1967).
Mihailova, D., Yamboliev, I., Zhivkova, Z., Tencheva, J., Jovovich, V.: "Pharmacokinetics of Galanthamine Hydrobromide after single subcutaneous and oral dosage in humans." Pharmacology, 39: 50-58 (1989).
Naranjo, C. A., Sellers, E. M. (Ed.): "Drug treatments for alcoholism: The need for innovation." in: Research Advances in New Psychoparm. Treatments for Alcoholism, 1-9 Elsevier Science Publishers B.V. (1985).
Paskov, D. S.: "Galanthamine." in: New Neuromuscular Blocking Agents, 31:653-72 Springer-Verlag Berlin, Heidelberg, New York, Tokyo (Ed.) (1986).
Snorrason, E., Stefansson, J. G.: "Galanthamine hydrobromide in mania." Lancet, 337: 557 (1991).
Stojek, A., Napierala, K.: "Physostigmine in eyedrops decreases craving for alcohol in early with withdrawal treated with carbamazepine." Materia Medica Polona, 4: 249-54 (1986).
Tanahashi, T., Poulev, a., Zenk, M. H.: "Radioimmunoassay for the quantitative determination of Galanthamine." Planta Medica, 56: 77-81 (1990).
Tencheva, J., Yamboliev, I., Zhivkova, Z.: "Reversed-phase liquid chromatography for the determination of galanthamine and its metabolites in human plasma and urine." Journal of Chromatography, 421: 396-400 (1987).
Thomsen, T., Bickel, U., Fischer, J. P., Kewitz, H.: "Stereoselectivity of cholinesterase inhibition by galanthamine and Eur. J. Clin. Pharmacol. and tolerance in humans" 39: 603-5 (1990).
Thomsen, T., Zendeh, B., Fischer, J. P., Kewitz, H.: "In vitro effects of various cholinesterase inhibitors on acetyl-- and butyrylchloinesterase of healthy volunteers." Biochemical Pharmacology, 41: 139-41 (1991).
Thomsen, T., Kaden, B. Fischer, J. P., Bickel, U., Barz, H., Gusztony, G., Cervos-Navarro, J. Kewitz, H.: "Inhibition of Acetylcholinesterase activity in human brain tissue and erythrocytes by Galanthamine, Physostigmine and Tacrine." Eur. J. Clin. Chem. Clin. Biochem., 29: 487-92 (1991).
Thomsen, T., Kewitz, H.: "Selective inhibition of human acetylcholinsterase by Galanthamine in vitro and in vivo." Life Sciences, 46: 1553-58 (1990).
Vlahov, R., Krikorian, D., Spassov, G., Chinova, M., Vlahov, I., Parushev, S., Snatzke, G., Ernst, L., Kieslich, K., Abraham, W.-R., Sheldrick, W. S.: "Synthesis of Galanthamine and related alkaloids-New approaches." Tetrahedron, 45: 3329-45 (1989).
J. Ruprecht et al: "The involvement of the central cholinergic and endorphinergic systems in the nitrous oxide withdrawal syndrome in mice." Anesthesiology, V. 58, No. 6, 1983, pp. 524-526.
Haboubi, N. A. et al, Ann. Clin. Biochem. 23(4): 458-62, 1986.
Hsu, L. L. et al., Alcohol Clin Exp Res 7(3); 249-55, 1983.
Stojek, A. et al., BR J Addict 82(8): 927-30; 1907.
Daunderer, M., Fortschr Med 101 (17); 778-80, 1983.
Power, J. S. et al.; J. Clin. Pharmacol. 21(1); 57-60, 1981.
Riley, E. P. et al., Alcohol Clin Exp Res 10(1); 50-53, 1986.
Rupreht, J. et al., Anesthesiology, 58(6), pp. 524-526, 1983.
Goodman Gilman et al., The Pharmacological Basis of Therapeutics (6th Ed.) Macmillan Publ. Co., N.Y., 1980, pp. 552-553.

Cintins, Marianne M.

Moezie M.

Sprung Horn Kramer & Woods

I claim:

1. A method of reducing the desire for alcohol in a patient suffering from alcoholism which comprises administering to such patient an amount effective to reduce the desire for alcohol of a material comprising galanthamine (4a, 5, 9, 10, 11, 12-hexahydro-3-methoxy-11-methyl-6H-benzofuro [3a, 3, 2-ef][2] benzazepine-6-ol) of the formula ##STR2## or a pharmaceutically acceptable acid addition salt thereof.

2. The method according to claim 1, wherein the material is administered orally.

3. The method according to claim 1, wherein the material is administered parenterally.

4. The method according to claim 1, wherein the material is administered transdermally.

5. The method according to claim 1, wherein the material is dissolved or dispersed in a liquid.

6. The method according to claim 4, wherein the material is in the form of an applicator comprising

7. The method according to claim 6, wherein the applicator also contains a membrane controlling the release of the active substance.

8. The method according to claim 6, wherein the applicator contains a removable protective layer.

9. The method according to claim 7, wherein the applicator contains a removable protective layer.